Lantheus Closes Sale of SPECT Business to SHINE Technologies

Reuters01-02
Lantheus Closes Sale of SPECT Business to SHINE Technologies

Lantheus Holdings Inc. has completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. The transaction includes the transfer of diagnostic agents such as TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®, as well as the portion of the North Billerica, Massachusetts campus dedicated to SPECT product manufacturing and related Canadian operations. Following this divestiture, Lantheus will focus on its commercial portfolio of PET radiodiagnostics, microbubbles, and advancing its radiopharmaceutical pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9618904-en) on January 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment